Bryan Dunnivant
Direktor/Vorstandsmitglied bei Intradigm Corp.
Profil
Mr. Bryan Dunnivant, CFA MBA, is Managing Director & Oxford Investment Fellow at Oxford Financial Group Ltd.
Prior to joining Oxford in 2015, he was Investment Director, Pension and Benefits, at Eli Lilly and Company.
In that role he had investment management and oversight responsibility for approximately $13 billion in assets.
His responsibilities included due diligence, manager selection and monitoring, performance evaluation and risk management.
He has over 25 years of leadership experience in the United States and Europe.
He holds a BS in Chemical Engineering from the University of Illinois.
He also holds an MBA from Butler University.
He is a CFA charter holder.
Aktive Positionen von Bryan Dunnivant
| Unternehmen | Position | Beginn |
|---|---|---|
Intradigm Corp.
 Intradigm Corp. Pharmaceuticals: MajorHealth Technology Intradigm Corp. develops drugs and therapies. Its RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. The company was founded by Puthupparampil Scaria, Martin C. Woodle, Wei-Wu He and Patrick Y. Lu in 2000 and is headquartered in Palo Alto, CA. | Direktor/Vorstandsmitglied | 01.01.2008 |
Ehemalige bekannte Positionen von Bryan Dunnivant
| Unternehmen | Position | Ende |
|---|---|---|
HemaQuest Pharmaceuticals, Inc.
 HemaQuest Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology HemaQuest Pharmaceuticals, Inc. develops small molecule therapeutics. Its products include hydroxyurea, a therapeutic agent for the treatment of underlying pathology of sickle cell anemia and for the treatments of beta thalassemia, sickle cell anemia, neutropenia, and various hematological disorders. The company was founded by Ronald J. Berenson, Douglas V. Faller, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos and Robert Williams in October 2007 and is headquartered in San Diego, CA. | Vorsitzender | 28.07.2010 |
| ELI LILLY AND COMPANY | Geschäftsführer | 31.12.2004 |
| PROTAGONIST THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | - |
Protagonist Pty Ltd.
 Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | Direktor/Vorstandsmitglied | - |
Fast Track Systems, Inc.
 Fast Track Systems, Inc. Packaged SoftwareTechnology Services Fast Track Systems, Inc. provides clinical trial software and professional services to pharmaceutical and biotechnology companies. It offers data-driven systems approach to expediting clinical trial design, setup and execution. The company was founded in 1991 and is headquartered in Conshohocken, PA. | Direktor/Vorstandsmitglied | - |
Ausbildung von Bryan Dunnivant
| University of Illinois | Undergraduate Degree |
| Butler University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| PROTAGONIST THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
LV Management Group, LLC
 LV Management Group, LLC Investment ManagersFinance Lilly Ventures Management Group LLC (Lilly ventures) is a venture capital firm, a subsidiary of Eli Lilly & Co. founded in 2001 by S.Edward Torres and Ron Laufer. The firm is headquartered in Indianapolis,Indiana. | Finance |
Fast Track Systems, Inc.
Fast Track Systems, Inc. Packaged SoftwareTechnology Services Fast Track Systems, Inc. provides clinical trial software and professional services to pharmaceutical and biotechnology companies. It offers data-driven systems approach to expediting clinical trial design, setup and execution. The company was founded in 1991 and is headquartered in Conshohocken, PA. | Technology Services |
HemaQuest Pharmaceuticals, Inc.
HemaQuest Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology HemaQuest Pharmaceuticals, Inc. develops small molecule therapeutics. Its products include hydroxyurea, a therapeutic agent for the treatment of underlying pathology of sickle cell anemia and for the treatments of beta thalassemia, sickle cell anemia, neutropenia, and various hematological disorders. The company was founded by Ronald J. Berenson, Douglas V. Faller, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos and Robert Williams in October 2007 and is headquartered in San Diego, CA. | Health Technology |
Protagonist Pty Ltd.
Protagonist Pty Ltd. Pharmaceuticals: MajorHealth Technology Protagonist Pty Ltd. operates as a clinical-stage biopharmaceutical company. Its proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The company was founded on September 19, 2001 and is headquartered in Brisbane, Australia. | Health Technology |
Intradigm Corp.
Intradigm Corp. Pharmaceuticals: MajorHealth Technology Intradigm Corp. develops drugs and therapies. Its RNAi therapeutic platform comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features. The company was founded by Puthupparampil Scaria, Martin C. Woodle, Wei-Wu He and Patrick Y. Lu in 2000 and is headquartered in Palo Alto, CA. | Health Technology |
